Perspectives on therapeutic HPV vaccines: Where are we now?

Connie Wang, Barbara Ma, Alexander Chen, Chien-Fu Hung, Tzyy Choou Wu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The role of Human Papillomavirus (HPV) as the key etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies. While the commercial preventive HPV vaccines Gardasil and Cervarix represent promising breakthroughs for the control of HPV-associated cancers through prevention, they do not exert therapeutic effects on existing lesions. In addition, their prohibitive cost and limited availability in developing countries, which account for >80% of cervical cancers, make it unlikely for the current preventive HPV vaccines to generate an immediate impact on the prevalence of cervical cancer. Thus, there is an urgent need for therapeutic HPV vaccines. HPV E6 and E7 oncoproteins represent ideal targets for therapeutic intervention because of their constitutive expression in HPV-associated tumors and their crucial role in the induction and maintenance of HPV-associated disease. This chapter focuses on the clinical development of various therapeutic HPV vaccines targeting E6 and/or E7 antigens, with perspectives on their future prospects for the control of HPV-associated malignancies.

Original languageEnglish (US)
Title of host publicationHPV and Cervical Cancer: Achievements in Prevention and Future Prospects
PublisherSpringer New York
Pages341-389
Number of pages49
ISBN (Print)9781461419884, 1461419875, 9781461419877
DOIs
StatePublished - Sep 1 2011

Fingerprint

Papillomavirus Vaccines
Uterine Cervical Neoplasms
Therapeutics
Neoplasms
Oncogene Proteins
Therapeutic Uses
Developing Countries
Maintenance
Antigens
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wang, C., Ma, B., Chen, A., Hung, C-F., & Wu, T. C. (2011). Perspectives on therapeutic HPV vaccines: Where are we now? In HPV and Cervical Cancer: Achievements in Prevention and Future Prospects (pp. 341-389). Springer New York. https://doi.org/10.1007/978-1-4614-1988-4_13

Perspectives on therapeutic HPV vaccines : Where are we now? / Wang, Connie; Ma, Barbara; Chen, Alexander; Hung, Chien-Fu; Wu, Tzyy Choou.

HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Springer New York, 2011. p. 341-389.

Research output: Chapter in Book/Report/Conference proceedingChapter

Wang, C, Ma, B, Chen, A, Hung, C-F & Wu, TC 2011, Perspectives on therapeutic HPV vaccines: Where are we now? in HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Springer New York, pp. 341-389. https://doi.org/10.1007/978-1-4614-1988-4_13
Wang C, Ma B, Chen A, Hung C-F, Wu TC. Perspectives on therapeutic HPV vaccines: Where are we now? In HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Springer New York. 2011. p. 341-389 https://doi.org/10.1007/978-1-4614-1988-4_13
Wang, Connie ; Ma, Barbara ; Chen, Alexander ; Hung, Chien-Fu ; Wu, Tzyy Choou. / Perspectives on therapeutic HPV vaccines : Where are we now?. HPV and Cervical Cancer: Achievements in Prevention and Future Prospects. Springer New York, 2011. pp. 341-389
@inbook{422a097cf4f944b283ac7771be230327,
title = "Perspectives on therapeutic HPV vaccines: Where are we now?",
abstract = "The role of Human Papillomavirus (HPV) as the key etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies. While the commercial preventive HPV vaccines Gardasil and Cervarix represent promising breakthroughs for the control of HPV-associated cancers through prevention, they do not exert therapeutic effects on existing lesions. In addition, their prohibitive cost and limited availability in developing countries, which account for >80{\%} of cervical cancers, make it unlikely for the current preventive HPV vaccines to generate an immediate impact on the prevalence of cervical cancer. Thus, there is an urgent need for therapeutic HPV vaccines. HPV E6 and E7 oncoproteins represent ideal targets for therapeutic intervention because of their constitutive expression in HPV-associated tumors and their crucial role in the induction and maintenance of HPV-associated disease. This chapter focuses on the clinical development of various therapeutic HPV vaccines targeting E6 and/or E7 antigens, with perspectives on their future prospects for the control of HPV-associated malignancies.",
author = "Connie Wang and Barbara Ma and Alexander Chen and Chien-Fu Hung and Wu, {Tzyy Choou}",
year = "2011",
month = "9",
day = "1",
doi = "10.1007/978-1-4614-1988-4_13",
language = "English (US)",
isbn = "9781461419884",
pages = "341--389",
booktitle = "HPV and Cervical Cancer: Achievements in Prevention and Future Prospects",
publisher = "Springer New York",

}

TY - CHAP

T1 - Perspectives on therapeutic HPV vaccines

T2 - Where are we now?

AU - Wang, Connie

AU - Ma, Barbara

AU - Chen, Alexander

AU - Hung, Chien-Fu

AU - Wu, Tzyy Choou

PY - 2011/9/1

Y1 - 2011/9/1

N2 - The role of Human Papillomavirus (HPV) as the key etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies. While the commercial preventive HPV vaccines Gardasil and Cervarix represent promising breakthroughs for the control of HPV-associated cancers through prevention, they do not exert therapeutic effects on existing lesions. In addition, their prohibitive cost and limited availability in developing countries, which account for >80% of cervical cancers, make it unlikely for the current preventive HPV vaccines to generate an immediate impact on the prevalence of cervical cancer. Thus, there is an urgent need for therapeutic HPV vaccines. HPV E6 and E7 oncoproteins represent ideal targets for therapeutic intervention because of their constitutive expression in HPV-associated tumors and their crucial role in the induction and maintenance of HPV-associated disease. This chapter focuses on the clinical development of various therapeutic HPV vaccines targeting E6 and/or E7 antigens, with perspectives on their future prospects for the control of HPV-associated malignancies.

AB - The role of Human Papillomavirus (HPV) as the key etiological factor for cervical cancer has spurred the development of preventive and therapeutic HPV vaccines for the control of HPV-associated malignancies. While the commercial preventive HPV vaccines Gardasil and Cervarix represent promising breakthroughs for the control of HPV-associated cancers through prevention, they do not exert therapeutic effects on existing lesions. In addition, their prohibitive cost and limited availability in developing countries, which account for >80% of cervical cancers, make it unlikely for the current preventive HPV vaccines to generate an immediate impact on the prevalence of cervical cancer. Thus, there is an urgent need for therapeutic HPV vaccines. HPV E6 and E7 oncoproteins represent ideal targets for therapeutic intervention because of their constitutive expression in HPV-associated tumors and their crucial role in the induction and maintenance of HPV-associated disease. This chapter focuses on the clinical development of various therapeutic HPV vaccines targeting E6 and/or E7 antigens, with perspectives on their future prospects for the control of HPV-associated malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84929524983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929524983&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-1988-4_13

DO - 10.1007/978-1-4614-1988-4_13

M3 - Chapter

AN - SCOPUS:84929524983

SN - 9781461419884

SN - 1461419875

SN - 9781461419877

SP - 341

EP - 389

BT - HPV and Cervical Cancer: Achievements in Prevention and Future Prospects

PB - Springer New York

ER -